Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins

Patent metadata

Field	Value
Publication number	US-12435377-B2
Application number	US-201917293381-A
Country	US
Kind code	B2
Filing date	Nov 13, 2019
Priority date	Nov 14, 2018
Publication date	Oct 7, 2025
Grant date	Oct 7, 2025

Abstract

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit arm-level loss of chromosome 16q, focal copy loss of 16q13 and/or low expression of metallothionein proteins, such as certain uterine, ovarian, gastroesophageal and lung cancers. Three known drugs, disulfiram, elesclomol and thiram, as well as certain disulfiram metabolites, are specifically provided for killing cancer cells characterized by arm-level loss of chromosome 16q, focal copy loss of 16q13 and/or low expression of metallothioneins. The instant disclosure therefore provides for selecting and/or administering disulfiram, elesclomol and thiram and/or active metabolites or derivatives of disulfiram, elesclomol and thiram as a therapeutic agent(s) to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.

First claim

We claim:

1. A pharmaceutical composition for arresting the development of or relieving a cancer in a subject having arm-level loss of 16q, focal copy loss of 16q13 and/or low expression of a metallothionein gene and/or protein, as compared to a control, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer, the pharmaceutical composition comprising a therapeutically effective amount of disulfiram, diethyldithiocarbamate (DDC), Cu-DDC, elesclomol, or thiram and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein:
the lung cancer is a NSCLC; and/or
the subject is human.

3. A method for selecting a treatment for arresting the development of or relieving a cancer in a subject, the method comprising:
(a) obtaining a sample from a subject having a cancer, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer;
(b) identifying one or more of the following: (i) arm-level loss of 16q, (ii) focal copy loss of 16q13, (iii) low expression of a metallothionein gene and/or protein in the sample, as compared to a control; and
(c) selecting disulfiram, diethyldithiocarbamate (DDC), Cu-DDC, elesclomol, or thiram as a treatment for administration to the subject when one or more of (i)-(iii) is identified in the sample,
thereby selecting a treatment for the subject.

4. The method of claim 1 , wherein the metallothionein gene and/or protein is a MT1 or MT2 isoform.

5. The method of claim 3 , wherein the metallothionein gene and/or protein is MT1E or MT2A.

6. The method of claim 3 , wherein low expression of MT1E or MT2A mRNA, as compared to a control, is identified.

7. The method of claim 3 , wherein methylation of the metallothionein gene is identified.

8. The method of claim 3 , wherein step (b) comprises identifying reduced MT1E or MT2A mRNA expression in the sample, as compared to a control.

9. The method of claim 3 , further comprising: (d) administering the selected treatment to the subject.

10. The method of claim 3 , wherein the treatment further comprises vinorelbine, a platinum agent, Letrozole, Anastrozole, Exemestane, Doxorubicin, Liposomal doxorubicin, Cyclophosphamide, Capecitabine, Docetaxel, Paclitaxel, Nab-paclitaxel, Trastuzumab, Ado-trastuzumab emtansine, Pertuzumab, Neratinib, Gemcitabine, Tamoxifen, Methotrexate, 5-Fluorouracil, Palbociclib, Abemaciclib, Fulvestrant, Olaparib, Eribulin, Pemetrexed, bevacizumab, nivolumab, pembrolizumab, ipilimumab, Oxaliplatin and/or ramucirumab.

11. The method of claim 3 , wherein identifying step (b) comprises use of a kit for identifying low expression of a metallothionein mRNA or protein in a sample, as compared to a control, the kit consisting essentially of an oligonucleotide for detection of a metallothionein mRNA or an anti-metallothionein antibody.

12. The method of claim 11 , wherein the kit comprises a labeled anti-metallothionein antibody or a labeled secondary antibody that binds an anti-metallothionein antibody.

13. The method of claim 1 , wherein the subject is human.

14. The method of claim 1 , wherein the cancer possesses, as compared to a control, one or more of the following: low MT1E mRNA expression levels, low MT1E protein expression levels, low MT2A mRNA expression levels and/or low MT2A protein expression levels.

15. The method of claim 3 , wherein the lung cancer is non-small cell lung cancer (NSCLC).

16. A method for arresting the development of or relieving a cancer in a subject, the method comprising:
(a) obtaining a sample from a subject having a cancer, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer;
(b) identifying in the sample one or more of the following: (i) arm-level loss of 16q, (ii) focal copy loss of 16q13; and
(c) administering disulfiram, diethyldithiocarbamate (DDC), Cu-DDC, elesclomol, or thiram to the subject when one or more of (i)-(ii) is identified in the sample,
thereby arresting the development of or relieving a cancer in the subject.

Assignees

• Broad Inst Inc
• Dana Farber Cancer Inst Inc
• Inst Carlos Slim De La Salud A C

Inventors

• Corsello Steven
• Spangler Ryan
• Nagari Rohith
• Golub Todd

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57545

  of the ovaries · CPC title

• G01N33/5755

  of the uterine cervix, uterine corpus or endometrium · CPC title

• G01N33/5752

  of the lungs · CPC title

• C12Q2600/158

  Expression markers · CPC title